Safe engineering of cancer-associated fibroblasts enhances checkpoint blockade immunotherapy

J Control Release. 2023 Apr:356:272-287. doi: 10.1016/j.jconrel.2023.02.041. Epub 2023 Mar 8.

Abstract

Abundant cancer-associated fibroblasts (CAFs) in highly fibrotic breast cancer constitute an immunosuppressive barrier for T cell activity and are closely related to the failure of immune checkpoint blockade therapy (ICB). Inspired by the similar antigen-processing capacity of CAFs to professional antigen-presenting cells (APCs), a "turning foes to friends" strategy is proposed by in situ engineering immune-suppressed CAFs into immune-activated APCs for improving response rates of ICB. To achieve safe and specific CAFs engineering in vivo, a thermochromic spatiotemporal photo-controlled gene expression nanosystem was developed by self-assembly of molten eutectic mixture, chitosan andfusion plasmid. After photoactivatable gene expression, CAFs could be engineered as APCs via co-stimulatory molecule (CD86) expression, which effectively induced activation and proliferation of antigen-specific CD8 + T cells. Meanwhile, engineered CAFs could also secrete PD-L1 trap protein in situ for ICB, avoiding potential autoimmune-like disorders caused by "off-target" effects of clinically applied PD-L1 antibody. The study demonstrated that the designed nanosystem could efficiently engineer CAFs, significantly enhance the percentages of CD8+ T cells (4-folds), result in about 85% tumor inhibition rate and 83.3% survival rate at 60 days in highly fibrotic breast cancer, further inducing long-term immune memory effects and effectively inhibiting lung metastasis.

Keywords: Antigen presentation; Cancer-associated fibroblasts; Immune checkpoint blockade therapy; Photoactivatable gene-expression; Thermochromic nanoparticles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-H1 Antigen
  • Breast Neoplasms* / metabolism
  • Cancer-Associated Fibroblasts* / metabolism
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / metabolism
  • Immunotherapy
  • Lung Neoplasms* / metabolism
  • Tumor Microenvironment

Substances

  • Immune Checkpoint Inhibitors
  • B7-H1 Antigen